Dewi Vernerey is a research engineer in epidemiology and biostatistics who received a master’s degree cum laude from Joseph Fourier University (Grenoble, France) with a major in  engineering statistics. He defended a PhD in epidemiology and statistics in 2016. His PhD research focused on statistical methodology for risk prediction and prognostic score construction in oncology and kidney transplantation.



    After working for 10 years in Paris at Gustave Roussy institute, Sanofi-Aventis, INSERM Unit 535 and Necker Hospital, he passed in 2009 the national health and medical research institute (INSERM) competitive examination for a research engineer permanent contract.  

    Then, he worked in an epidemiology unit at the Cardiovascular Research Center of Paris (PARCC) located in Georges Pompidou European hospital. In 2013, he decided to join the  Methodology and quality of life unit in Oncology (UMQVC) at the University hospital of Besancon with his engineer permanent contract. He teaches statistics, data Analysis and methodology in master’s degree and in medical school. 

    Since 2017, he is the head of the “Epidemilogy and Biostatistics” UMQVC’s module and the head of the GERCOR statistical team (INCAS’s labelled data center). He is also a member of the ARCAD foundation and of the HaliodDx’s Scientific Advisory Boards.


Research thematic:

  • Methodology in prognostic research and risk stratification
  • Development and improvement of prognostic and/or predictive tools at population and individual level. 

Main areas of expertise:  

  • Statistics and epidemiology
  • Clinical trial design ans analysis
  • Clinical research
  • Genetic epidemiology (linkage and association analyses)
  • Oncology
  • Solid transplantation (kidney and heart)
  • Cardiology

Main ongoing external collaborations :

  • GERCOR (Multidisciplinary Group in Oncology)
  • Fondation ARCAD (Aide et Recherche en Cancérologie Digestive)
  • AGEO (Association des Gastro-Entérologues Oncologues)
  • FRENCH (Fédération de Recherche EN Chirurgie)

Tools online

  • Prognostic Score and Nomogram to Predict Overall Survival in Locally Advanced Pancreatic Cancer: The PROLAP score 
  • Prognostic Nomogram and Score to Predict Overall Survival in Second Line Chemotherapy for Advanced Pancreatic Cancer: The PROSCAP score 

Principaux articles

sample

AbstractPURPOSE:The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : JCO

sample

AbstractOBJECTIVES:To assess the long term outcomes of transplantation using expanded criteria donors (ECD; donors aged...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : BMJ

sample

AbstractBACKGROUND:The combination of an anti-VEGF or an anti-EGFR-targeted monoclonal antibody with chemotherapy has...

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Nom de la revue : Lancet Oncol

sample

Background: In advanced pancreatic ductal adenocarcinoma (aPDAC), there is no consensual strategy for...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN, Mme. Aurélia MEURISSE
Nom de la revue : JNCI J Natl Cancer Inst

sample

BACKGROUND:Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : New England Journal of Medicine

Derniers articles

sample

In first-line metastatic colorectal cancer (mCRC), baseline prognostic factors allowing death risk and treatment...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : International Journal of Cancer

sample

AbstractBACKGROUND:The combination of an anti-VEGF or an anti-EGFR-targeted monoclonal antibody with chemotherapy has...

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Nom de la revue : Lancet Oncol

sample

BackgroundPatients treated with chemotherapy for microsatellite unstable (MSI) and/or mismatch repair deficient (dMMR)...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Eur J Cancer

sample

Abstract Background: Baseline prognostic biomarkers stratifying treatmentstrategies in first-line metastatic...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue :

sample

Background: The management of locally advanced pancreatic cancer (LAPC) patients remains controversial. Better...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : British Journal of Cancer

sample

AbstractBACKGROUND:We investigated whether the health-related quality of life (HRQoL) score is a prognostic factor for...

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY,
Nom de la revue : EJC

sample

ABSTRACTPurpose Reduction of adjuvant treatment duration may decrease toxicities without loss of efficacy in stage III...

Posté par : Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY, Pr. Franck BONNETAIN
Nom de la revue : Journal of Clinical Oncology

sample

AbstractAIM:Microarray studies identified a subgroup of molecular apocrine tumors (estrogen receptor [ER]...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Future Oncol

sample

AbstractBackground: Frailty is highly prevalent in elderly people. While significant progress has been made to...

Posté par : Dr. Dewi VERNEREY, Dr. Amélie ANOTA, Dr. Sophie PAGET-BAILLY, Mme. Audrey FOUBERT, Mme. Astrid POZET, Pr. Franck BONNETAIN
Nom de la revue : BMC Geriatrics

sample

AbstractGlioblastoma is the most common malignant brain tumor in adults. Baselinehealth-relatedquality of life (HRQoL)...

Posté par : , Dr. Dewi VERNEREY, Dr. Amélie ANOTA, Pr. Franck BONNETAIN
Nom de la revue : Cancer Medicine

Dernières actualités

Derniers outils

The R package QoLR allows to compute the scoring of main EORTC quality of life questionnaires and to perform the...

Posté par : Dr. Amélie ANOTA, Dr. Dewi VERNEREY, Dr. Amélie ANOTA, Pr. Franck BONNETAIN, Dr. Amélie ANOTA

The management of locally advanced pancreatic cancer (LAPC) patients remains controversial. Better discrimination for...

Posté par : Pr. Franck BONNETAIN, Dr. Sophie PAGET-BAILLY, Dr. Dewi VERNEREY

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY

Currently, the management of advanced pancreatic cancer patients is complex in second-line palliative chemotherapy...

Posté par : Dr. Dewi VERNEREY, Dr. Angélique VIENOT

2015-2018 © Copyright - UMQVC.org

Website by Pearlweb